- Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)Chen, Jinzhang; Zang, Mengya; Pang, Huajin; Li, Chuanjiang; Zhao, Jianbo; Guo, Yabing; Hou, JinlinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 1
- Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trialQin, S.; Chan, L. S.; Gu, S.; Bai, Y.; Ren, Z.; Lin, X.; Chen, Z.; Jia, W.; Jin, Y.; Guo, Y.; Sultanbaev, A. V.; Pazgan-Simon, M.; Pisetska, M.; Liang, X.; Chen, C.; Nie, Z.; Wang, L.; Cheng, A-L.; Kaseb, A.; Vogel, A.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 85
- The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trialBai, L.; Bai, Y.; Huang, M.; Shao, G.; Song, L.; Sun, M.; Wang, W.; Wu, J.; Xu, A.; Huang, L.; Liu, T.; Liu, W.; Wang, Z. M.; Li, B.; Xia, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)
14阅读
